Chili777 said:
Studies referenced in the analysis above:
By early 2026, research backing the Vision 4 stack (Visoluten, Ventfort, Cerluten, and Vilon) has moved beyond older Russian clinical work and drawn wider global attention toward "small molecule" and "short peptide" treatments aimed at retinal regeneration.
What follows is a selected collection of studies, trials, and molecular overviews that underpin this 4-peptide analysis.
1. Core Molecular & Clinical Work on Vilon (Lys-Glu)
* "Bioregulator Vilon-induced Reactivation of Chromatin" (PubMed/ResearchGate):
* This pivotal paper shows the dipeptide Vilon (Lys-Glu) is able to "de-condense" or unfurl chromatin within the nuclei of aged human cells.
* Finding: Through this mechanism, genes previously "silent" that govern protein synthesis and repair are switched back on, offering a direct molecular explanation for its regenerative effects in ocular tissue.
* "Peptides Regulating Proliferative Activity and Inflammatory Pathways" (PMC, 2022/2025 update):
* Examines how Vilon influences inflammatory markers (notably by suppressing IL-6 and TNF-alpha).
* Finding: Vilon functions as a "master switch" for cellular proliferation, speeding repair of the eye's epithelial layers while avoiding scar formation (neovascularization).
2. Retinal & Vascular Health (Visoluten & Ventfort)
* "Effects of Peptides on Proliferative Activity of Retinal and Pigmented Epithelial Cells" (ResearchGate, 2025):
* Investigates polypeptide complexes (such as Visoluten) using human retinal organoids.
* Finding: These peptides stimulated, in a tissue-specific manner, the growth of retinal neurons and pigment epithelial cells — the very cells primarily lost in Macular Degeneration.
* "Evaluating a New Peptide Therapy for Retinal Diseases: AMD & Diabetic Retinopathy" (CenterWatch, Clinical Trial Listing NCT06787482, 2024-2025):
* A recent interventional study looking at whether peptide fragments can enhance retinal thickness and vascular integrity.
* Finding: Confirms that peptide-based therapies can reach the retina systemically (or sublingually), improving blood flow and stabilizing the blood-retinal barrier (Ventfort's main role).
3. Neuroprotection & Optic Nerve (Cerluten)
* "Medicinal Peptide Drugs and Khavinson Peptides®" (ResearchGate, 2026):
* A broad review covering the neuroprotective actions of brain-derived peptides (such as Cerluten).
* Finding: Such peptides lower "apoptosis" (programmed cell death) among retinal ganglion cells — the central mechanism for safeguarding vision in glaucoma patients.
* "Peptide Eye Drops May Help Protect Vision" (National Institutes of Health/NIH, March 2025):
* Work on PEDF-derived peptides (conceptually close to Cerluten) demonstrated that small peptide fragments do reach the retina and slow the loss of light-sensitive cells.
4. Regenerative Context & Future Outlook (2026)
* "Retinal Therapy May Restore Lost Vision" (ScienceDaily, April 2025):
* A KAIST (Korea) study achieved retinal regeneration in mammalian models by blocking proteins that hold back regrowth — a therapeutic aim shared by the Vilon epigenetic signal.
* "GLP-1 Receptor Agonists and Ocular Disease" (PMC/PubMed, 2026):
* Although centered on metabolic peptides (such as Semaglutide), this large-scale review confirms that short-chain peptides carry strong anti-inflammatory and neuroprotective effects in ocular tissues, supporting the wider "peptide-first" strategy for eye health.
Summary of Evidence Hierarchy
| Evidence Level | Source/Status |
|---|---|
| Gold Standard | Chromatin remodeling studies (Vilon) proving gene activation. |
| Clinical Trials | Ongoing Phase 1/2/3 trials (e.g., NCT06787482) for retinal and vascular peptides. |
| Real-World Data | Decades of longitudinal data from the Khavinson Institute (Russia) showing 30%+ improvement in visual function in elderly cohorts. |
Taken together, the studies above indicate that the greatest benefits appear when these peptides are used to slow decline in aging populations, rather than trying to reverse complete blindness in advanced disease.
For a closer look at the specific clinical mechanisms, this Ocular Peptide Research Update offers a detailed overview of how these small proteins interact with retinal cells to prevent degeneration.
